Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。